# US 2021/0277149 A1 · Anti-idiotype antibodies and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277149 A1
- Document ID: US20210277149A1
- Status: Published application
- Kind: A1
- Application number: 17/191,694
- Filed: 2021-03-03
- Published: 2021-09-09
- Earliest claimed: 2020-03-06
- Assignees: Mustang Bio, Inc.
- Applicants: Mustang Bio, Inc.
- Inventors: Ekta PATEL; Junxia WANG; Ajit KAMATH; Nathan K GUMLAW
- Web page: https://patentgrep.com/patent/US20210277149A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/4258: {against anti-receptor Ig}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4217: {Receptors for interleukins [IL]}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/4208: {against an idiotypic determinant on Ig}
- C07K 16/4241: {against anti-human or anti-animal Ig}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- G01N 33/56972: {White blood cells}
- G01N 33/686: {Anti-idiotype}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2501/50: Cell markers; Cell surface determinants
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates generally to antibodies and binding fragments thereof that bind to anti-CD123 antibodies, chimeric antigen receptors (CARs), or antibody binding fragments. In particular, the disclosed anti-idiotype antibodies and fragments bind to anti-CD123 antibodies, CARs, or fragments thereof and comprise novel complementary determining regions (CDRs). Finally, the present disclosure relates to methods of using the disclosed antibodies and fragments thereof to expand and/or activate CD123-CAR-expressing immune cells, detecting or quantifying CD123-CARs, and isolating CD123-CAR-expressing immune cells.

## Claims

### Claim 1

An antibody or antigen-binding fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region, the VH and VL regions comprising a heavy chain complementarity determining region 1 (CDRH1) comprising GFNIKDSF (SEQ ID NO: 1), a CDRH2 comprising IDPEDDET (SEQ ID NO: 2), and a CDRH3 comprising ASPIYGSREAWFAY (SEQ ID NO: 3), and a light chain complementarity determining region 1 (CDRL1) comprising EDIYX1X2 (SEQ ID NO: 10), a CDRL2 comprising X3AX4 (SEQ ID NO: 11), and a CDRL3 comprising QQX5X6X7YPX8T (SEQ ID NO: 12),
wherein X1 is a polar amino acid; X2 is selected from the group consisting of serine (S), threonine (T), asparagine (N), glutamine (Q), cysteine (C), glycine (G), and proline (P); X3 is selected from the group consisting of aspartic acid (D), glutamic acid (E), serine (S), threonine (T), asparagine (N), and glutamine (Q); X4 is a polar amino acid; X5 and X6 are selected from the group consisting of arginine (R), histidine (H), lysine (K), alanine (A), valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tyrosine (Y), and tryptophan (W); X7 is selected from the group consisting of aspartic acid (D), glutamic acid (E), serine (S), threonine (T), asparagine (N), and glutamine (Q); and X8 is selected from the group consisting of alanine (A), valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tyrosine (Y), and tryptophan (W).

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein X1 is serine (S) or asparagine (N); X2 is asparagine (N) or glycine (G); X3 is aspartic acid (D) or asparagine (N); wherein X4 is serine (S) or asparagine (N); X5 and X6 are histidine (H) or tyrosine (Y); X7 is aspartic acid (D) or asparagine (N); or X8 is leucine (L) or tyrosine (Y).

### Claim 3 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein X1 is serine (S) or asparagine (N); X2 is asparagine (N) or glycine (G); X3 is aspartic acid (D) or asparagine (N); wherein X4 is serine (S) or asparagine (N); X5 and X6 are histidine (H) or tyrosine (Y); X7 is aspartic acid (D) or asparagine (N); and X8 is leucine (L) or tyrosine (Y).

### Claim 4 (depends on 1)

The antibody or antigen-binding fragment of claim 1, comprising:
a) a CDRH1 comprising GFNIKDSF (SEQ ID NO: 1), a CDRH2 comprising IDPEDDET (SEQ ID NO: 2), and a CDRH3 comprising ASPIYGSREAWFAY (SEQ ID NO: 3), and a CDRL1 comprising EDIYSN (SEQ ID NO: 4), a CDRL2 comprising DAS (SEQ ID NO: 5), and a CDRL3 comprising QQHHDYPLT (SEQ ID NO: 6); or
b) a CDRH1 comprising GFNIKDSF (SEQ ID NO: 1), a CDRH2 comprising IDPEDDET (SEQ ID NO: 2), and a CDRH3 comprising ASPIYGSREAWFAY (SEQ ID NO: 3), and a CDRL1 comprising EDIYNG (SEQ ID NO: 7), a CDRL2 comprising NAN (SEQ ID NO: 8), and a CDRL3 comprising QQYYNYPYT (SEQ ID NO: 9).

### Claim 5 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein:
a) the VH region comprises
EVQLQQSGAELVRPGASVRLSCTTSGFNIKDSFIHWVKQRTEQGLEWIGRI DPEDDETKYAPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCASPIYG SREAWFAYWGQGTLVTVSA (SEQ ID NO: 13) and the VL comprises DIQMTQSPASLSASLGETVTIECLASEDIYSNLAWYQQKPGKSPQLLIYDA SSLQDGVPSRFSGSESGTQYSLEINSLQSEDAATYFCQQHHDYPLTFGSGT KLEIK (SEQ ID NO: 14); or
b) the VH region comprises
EVQLQQSGAELVRPGASVRLSCTTSGFNIKDSFIHWVKQRTEQGLEWIGRI DPEDDETKYAPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCASPIYG SREAWFAYWGQGTLVTVSA (SEQ ID NO: 13) and the VL comprises DIQMTQSPASLSASLGETVTIECRASEDIYNGLAWYQQKPGKSPQLLIYNA NSLHTGVPSRFSGSGSGTQYSLKINSLQSEDVASYFCQQYYNYPYTFGAG TKLELK (SEQ ID NO: 15).

### Claim 6 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein the antibody or antigen-binding fragment specifically binds to an idiotype on an anti-CD123 antibody or an anti-CD123 antigen-binding fragment.

### Claim 7 (depends on 6)

The antibody or antigen-binding fragment of claim 6, wherein the anti-CD123 antibody or anti-CD123 antigen-binding fragment comprises the VL domain of
DVQITQSPSYLAASPGETITINCRASKSISKDLAWYQEKPGKTNKLLIYSGSTLQS GIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNKYPYTFGGGTKLEIK (SEQ ID NO: 20) and/or the VH domain of
QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWMNWVKQRPDQGLEWIGRIDP YDSETHYNQKFKDKAILTVDKSSSTAYMQLSSLTSEDSAVYYCARGNWDDYWG QGTTLTVSS (SEQ ID NO: 21).

### Claim 8 (depends on 6)

The antibody or antigen-binding fragment of claim 6, wherein the anti-CD123 antigen-binding fragment is incorporated into a chimeric antigen receptor (CAR).

### Claim 9 (depends on 8)

The antibody or antigen-binding fragment of claim 8, wherein the CAR comprises:
a) an IgG hinge or a modified IgG hinge,
b) a transmembrane domain,
c) a co-stimulatory signaling domain, and
d) T cell receptor zeta chain signaling domain.

### Claim 10 (depends on 9)

The antibody or antigen-binding fragment of claim 9, wherein the co-stimulatory signaling domain is selected from the group consisting of: a CD27 co-stimulatory signaling domain, a CD28 co-stimulatory signaling domain, a 4-1BB co-stimulatory signaling domain, and an OX40 co-stimulatory signaling domain; and wherein the transmembrane domain comprises a transmembrane portion of CD28, CD4, CD8, 4-1BB, CD27, ICOS, OX40, HVEM, or CD30.

### Claim 11 (depends on 8)

The antibody or antigen-binding fragment of claim 8, wherein the CAR comprises a VL domain comprising SEQ ID NO: 20 and VH domain comprising SEQ ID NO: 21, a CD28 transmembrane domain, a co-stimulatory domain comprising SEQ ID NO: 24 or SEQ ID NO: 25, and a CD3ζ domain comprising SEQ ID NO: 48.

### Claim 12 (depends on 8)

The antibody or antigen-binding fragment of claim 8, wherein the CAR comprises a VL domain comprising SEQ ID NO: 22 and VH domain comprising SEQ ID NO: 23, a CD28 transmembrane domain, a co-stimulatory domain comprising SEQ ID NO: 24 or SEQ ID NO: 25, and a CD3ζ domain comprising SEQ ID NO: 48.

### Claim 13 (depends on 8)

The antibody or antigen-binding fragment of claim 8, wherein the CAR comprises SEQ ID NO: 49 or SEQ ID NO: 50.

### Claim 14

A nucleotide sequence encoding an antibody or antigen-binding fragment comprising:
(SEQ ID NO: 16)
a) GAGGTTCAGCTGCAGCAGTCTGGGGCAGAGCTTGTGAGGCCAGG
GGCCTCAGTCAGGTTGTCCTGCACAACTTCTGGCTTCAACATTAAAG
ACTCCTTTATTCACTGGGTGAAGCAGAGGACTGAACAGGGCCTGGAG
TGGATTGGAAGGATTGATCCTGAGGATGATGAAACTAAATATGCCCC
GAAATTCCAGGGCAAGGCCACTATAACAGCAGACACATCCTCCAACA
CAGCCTACCTGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTC
TATTACTGTGCTAGCCCCATCTACGGTAGTAGAGAGGCCTGGTTTGC
TTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA
and
(SEQ ID NO: 17)
GACATCCAGATGACACAGTCTCCAGCTTCCCTGTCTGCATCTCTGGG
AGAAACTGTCACCATCGAATGTCTAGCAAGTGAAGACATTTACAGTA
ATTTAGCGTGGTATCAGCAGAAGCCAGGGAAATCTCCTCAGCTCCTG
ATCTATGATGCAAGTAGCTTGCAAGATGGGGTCCCATCACGGTTCAG
TGGCAGTGAATCTGGCACACAGTATTCTCTCGAGATCAACAGCCTGC
AATCTGAAGATGCCGCGACTTATTTCTGTCAACAGCATCATGATTAT
CCTCTCACGTTCGGTTCTGGGACCAAGCTGGAGATCAAA;
or
(SEQ ID NO: 18)
b) GAGGTTCAGCTGCAGCAGTCTGGGGCAGAGCTTGTGAGGCCAGG
GGCCTCAGTCAGGTTGTCCTGCACAACTTCTGGCTTCAACATTAAAG
ACTCCTTTATTCACTGGGTGAAGCAGAGGACTGAACAGGGCCTGGAG
TGGATTGGAAGGATTGATCCTGAGGATGATGAAACTAAATATGCCCC
GAAATTCCAGGGCAAGGCCACTATAACAGCAGACACATCCTCCAACA
CAGCCTACCTGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTC
TATTACTGTGCTAGCCCCATCTACGGTAGTAGAGAGGCCTGGTTTGC
TTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA
and
(SEQ ID NO: 19)
GACATCCAGATGACACAGTCTCCAGCTTCCCTGTCTGCATCTCTGGG
AGAAACTGTCACCATCGAATGTCGAGCAAGTGAGGACATTTACAATG
GTTTAGCATGGTATCAGCAGAAGCCAGGGAAATCTCCTCAGCTCCTG
ATCTATAATGCAAATAGCTTGCATACTGGGGTCCCATCACGGTTCAG
TGGCAGTGGATCTGGTACACAGTATTCTCTCAAGATAAACAGCCTGC
AGTCTGAAGATGTCGCAAGTTATTTCTGTCAACAGTATTACAATTAT
CCGTACACGTTTGGAGCTGGGACCAAGCTGGAACTGAAA.

### Claim 15 (depends on 14)

An expression vector comprising the nucleotide sequence of claim 14.

### Claim 16

A method of expanding or activating immune cells that express an anti-CD123 chimeric antigen receptor (CD123-CAR) comprising contacting in vitro a population of immune cells that express a CD123-CAR with an anti-idiotype antibody or antigen-binding fragment that specifically binds to an idiotype of the CD123-CAR, wherein the CD123-CAR comprises a scFv that binds to CD123, a hinge domain, a transmembrane domain, a co-stimulatory domain, and T cell receptor zeta chain signaling domain.

### Claim 17 (depends on 16)

The method of claim 16, wherein the anti-idiotype antibody or antigen-binding fragment comprises:
a) a CDRH1 comprising GFNIKDSF (SEQ ID NO: 1), a CDRH2 comprising IDPEDDET (SEQ ID NO: 2), and a CDRH3 comprising ASPIYGSREAWFAY (SEQ ID NO: 3), and a CDRL1 comprising EDIYSN (SEQ ID NO: 4), a CDRL2 comprising DAS (SEQ ID NO: 5), and a CDRL3 comprising QQHHDYPLT (SEQ ID NO: 6); or
b) a CDRH1 comprising GFNIKDSF (SEQ ID NO: 1), a CDRH2 comprising IDPEDDET (SEQ ID NO: 2), and a CDRH3 comprising ASPIYGSREAWFAY (SEQ ID NO: 3), and a CDRL1 comprising EDIYNG (SEQ ID NO: 7), a CDRL2 comprising NAN (SEQ ID NO: 8), and a CDRL3 comprising QQYYNYPYT (SEQ ID NO: 9).

### Claim 18 (depends on 16)

The method of claim 16, wherein the anti-idiotype antibody or antigen-binding fragment comprises:
a) a VH region comprising
EVQLQQSGAELVRPGASVRLSCTTSGFNIKDSFIHWVKQRTEQGLEWIGRI DPEDDETKYAPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCASPIYG SREAWFAYWGQGTLVTVSA (SEQ ID NO: 13) and a VL comprising DIQMTQSPASLSASLGETVTIECLASEDIYSNLAWYQQKPGKSPQLLIYDA SSLQDGVPSRFSGSESGTQYSLEINSLQSEDAATYFCQQHHDYPLTFGSGT KLEIK (SEQ ID NO: 14); or
b) a VH region comprising
EVQLQQSGAELVRPGASVRLSCTTSGFNIKDSFIHWVKQRTEQGLEWIGRI DPEDDETKYAPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCASPIYG SREAWFAYWGQGTLVTVSA (SEQ ID NO: 13) and a VL comprising DIQMTQSPASLSASLGETVTIECRASEDIYNGLAWYQQKPGKSPQLLIYNA NSLHTGVPSRFSGSGSGTQYSLKINSLQSEDVASYFCQQYYNYPYTFGAG TKLELK (SEQ ID NO: 15).

### Claim 19 (depends on 16)

The method of claim 16, wherein the co-stimulatory signaling domain of the CD123-CAR is selected from the group consisting of: a CD27 co-stimulatory signaling domain, a CD28 co-stimulatory signaling domain, a 4-1BB co-stimulatory signaling domain, and an OX40 co-stimulatory signaling domain; and wherein the transmembrane domain comprises a transmembrane portion of CD28, CD4, CD8, 4-1BB, CD27, ICOS, OX40, HVEM, or CD30.

### Claim 20 (depends on 16)

The method of claim 16, wherein the scFv of the CD123-CAR comprises SEQ ID NOs: 20 and 21 or SEQ ID NOs: 22 and 23.

### Claim 21 (depends on 16)

The method of claim 16, wherein the CD123-CAR comprises SEQ ID NO: 49 or SEQ ID NO: 50.

### Claim 22 (depends on 16)

The method of claim 16, wherein the immune cells are T cells or natural killer (NK) cells.

### Claim 23

A method of detecting the presence of a CD123-CAR in a sample comprising, contacting a sample comprising immune cells that are suspected of expressing a CD123-CAR with an anti-idiotype antibody or antigen-binding fragment that specifically binds to an idiotype of the CD123-CAR and quantifying the number of cells expressing the CD123-CAR, wherein the CD123-CAR comprises a scFv that binds to CD123, a hinge domain, a transmembrane domain, at least one co-stimulatory domain, and T cell receptor zeta chain signaling domain.

### Claim 24 (depends on 23)

The method of claim 23, wherein the anti-idiotype antibody or antigen-binding fragment comprises:
a) a CDRH1 comprising GFNIKDSF (SEQ ID NO: 1), a CDRH2 comprising IDPEDDET (SEQ ID NO: 2), and a CDRH3 comprising ASPIYGSREAWFAY (SEQ ID NO: 3), and a CDRL1 comprising EDIYSN (SEQ ID NO: 4), a CDRL2 comprising DAS (SEQ ID NO: 5), and a CDRL3 comprising QQHHDYPLT (SEQ ID NO: 6); or
b) a CDRH1 comprising GFNIKDSF (SEQ ID NO: 1), a CDRH2 comprising IDPEDDET (SEQ ID NO: 2), and a CDRH3 comprising ASPIYGSREAWFAY (SEQ ID NO: 3), and a CDRL1 comprising EDIYNG (SEQ ID NO: 7), a CDRL2 comprising NAN (SEQ ID NO: 8), and a CDRL3 comprising QQYYNYPYT (SEQ ID NO: 9).

### Claim 25 (depends on 23)

The method of claim 23, wherein the anti-idiotype antibody or antigen-binding fragment comprises:
a) a VH region comprising
EVQLQQSGAELVRPGASVRLSCTTSGFNIKDSFIHWVKQRTEQGLEWIGRI DPEDDETKYAPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCASPIYG SREAWFAYWGQGTLVTVSA (SEQ ID NO: 13) and a VL comprising DIQMTQSPASLSASLGETVTIECLASEDIYSNLAWYQQKPGKSPQLLIYDA SSLQDGVPSRFSGSESGTQYSLEINSLQSEDAATYFCQQHHDYPLTFGSGT KLEIK (SEQ ID NO: 14); or
b) a VH region comprising
EVQLQQSGAELVRPGASVRLSCTTSGFNIKDSFIHWVKQRTEQGLEWIGRI DPEDDETKYAPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCASPIYG SREAWFAYWGQGTLVTVSA (SEQ ID NO: 13) and a VL comprising DIQMTQSPASLSASLGETVTIECRASEDIYNGLAWYQQKPGKSPQLLIYNA NSLHTGVPSRFSGSGSGTQYSLKINSLQSEDVASYFCQQYYNYPYTFGAG TKLELK (SEQ ID NO: 15).

### Claim 26 (depends on 23)

The method of claim 23, wherein the immune cells are T cells or natural killer (NK) cells.

### Claim 27 (depends on 23)

The method of claim 23, wherein the CD123-CAR comprises a VL domain comprising SEQ ID NO: 20 and VH domain comprising SEQ ID NO: 21, a CD28 transmembrane domain, a co-stimulatory domain comprising SEQ ID NO: 24 or SEQ ID NO: 25, and a CD3ζ domain comprising SEQ ID NO: 48; or wherein the CD123-CAR comprises a VL domain comprising SEQ ID NO: 22 and VH domain comprising SEQ ID NO: 23, a CD28 transmembrane domain, a co-stimulatory domain comprising SEQ ID NO: 24 or SEQ ID NO: 25, and a CD3ζ domain comprising SEQ ID NO: 48.

### Claim 28 (depends on 23)

The method of claim 23, wherein the CD123-CAR comprises SEQ ID NO: 49 or SEQ ID NO: 50.

### Claim 29 (depends on 23)

The method of claim 23, wherein the sample is a cell culture medium.

### Claim 30 (depends on 23)

The method of claim 23, wherein the sample is a blood sample from a subject that has been treated with the immune cells expressing the CD123-CAR.

### Claim 31

A method of isolating immune cells that express an CD123-CAR from a sample comprising, contacting a sample comprising immune cells that are suspected of expressing an CD123-CAR with a solid support comprising an anti-idiotype antibody or antigen-binding fragment comprising:
a) a CDRH1 comprising GFNIKDSF (SEQ ID NO: 1), a CDRH2 comprising IDPEDDET (SEQ ID NO: 2), and a CDRH3 comprising ASPIYGSREAWFAY (SEQ ID NO: 3), and a CDRL1 comprising EDIYSN (SEQ ID NO: 4), a CDRL2 comprising DAS (SEQ ID NO: 5), and a CDRL3 comprising QQHHDYPLT (SEQ ID NO: 6); or
b) a CDRH1 comprising GFNIKDSF (SEQ ID NO: 1), a CDRH2 comprising IDPEDDET (SEQ ID NO: 2), and a CDRH3 comprising ASPIYGSREAWFAY (SEQ ID NO: 3), and a CDRL1 comprising EDIYNG (SEQ ID NO: 7), a CDRL2 comprising NAN (SEQ ID NO: 8), and a CDRL3 comprising QQYYNYPYT (SEQ ID NO: 9);
thereby isolating the immune cells that express the CD123-CAR from the sample, wherein the CD123-CAR comprises a scFv that binds to CD123, a hinge domain, a transmembrane domain, a co-stimulatory domain, and T cell receptor zeta chain signaling domain.

### Claim 32 (depends on 31)

The method of claim 31, wherein the sample is a cell culture medium.

### Claim 33 (depends on 31)

The method of claim 31, wherein the sample is a blood sample from a subject that has been treated with the immune cells expressing the CD123-CAR.

### Claim 34 (depends on 31)

The method of claim 31, wherein the solid support comprising a column or beads to which the anti-idiotype antibody or antigen-binding fragment is linked.

### Claim 35 (depends on 31)

The method of claim 31, wherein the CD123-CAR comprises SEQ ID NO: 49 or SEQ ID NO: 50.
